Company: SRPT
Filing Date: 2025-08-21
Form Type: 8-K
Source: 0001193125-25-184625
Chunk: 2

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-08-21
Form: 8-K
Item: Item 3.02
Chunk 2
---
 price of our Common Stock on August 27, 2025 and (y) $14.41, rounded down to the nearest whole share, representing gross proceeds of approximately $20.0 million. In addition, we have entered into an engagement letter, dated August 18, 2025 (the “ Engagement Letter”) with JWCA, pursuant to which JWCA may elect to receive up to 835,765 shares of our Common Stock in lieu of a fee for financial advisory services (the “ Fee Shares”).

The issuance of the New Convertible Notes and the Shares under the Exchange Agreements, the PIPE Shares under the Subscription Agreement and the Fee Shares under the Engagement Letter is being made in reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended (the “ Securities Act”), provided by Section 4(a)(2) of the Securities Act. The New Convertible Notes, the Shares and the PIPE Shares will be issued only to investors that qualified as institutional “accredited investors” (as such term is defined in Rule 501 of the Securities Act) and “qualified institutional buyers” (as such term is defined in Rule 144A of the Securities Act).

The New Convertible Notes, the Shares, the PIPE Shares and the Fee Shares have not been registered under the Securities Act or the securities laws of any state or other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and such other jurisdictions.

Forward-Looking Statements

This Current Report on Form 8-K 10-Q 8-K.